195 related articles for article (PubMed ID: 28478613)
21. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
22. Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM; Bürger H; van Diest PJ; Finsterbusch K; Gläser D; Korsching E; Decker T;
Eur J Cancer; 2017 Oct; 84():219-227. PubMed ID: 28829990
[TBL] [Abstract][Full Text] [Related]
23. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
24. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
25. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
Yamamoto S; Ibusuki M; Yamamoto Y; Fu P; Fujiwara S; Murakami K; Iwase H
Breast Cancer; 2013 Jul; 20(3):262-70. PubMed ID: 22362219
[TBL] [Abstract][Full Text] [Related]
27. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.
Ruiz C; Seibt S; Al Kuraya K; Siraj AK; Mirlacher M; Schraml P; Maurer R; Spichtin H; Torhorst J; Popovska S; Simon R; Sauter G
Int J Cancer; 2006 May; 118(9):2190-4. PubMed ID: 16331604
[TBL] [Abstract][Full Text] [Related]
28. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study.
Oshiro H; Czerniak BA; Sakamaki K; Tsuta K; Bondaruk J; Keyhani A; Dinney CP; Nagai T; Kamat AM
Medicine (Baltimore); 2016 Aug; 95(31):e4500. PubMed ID: 27495099
[TBL] [Abstract][Full Text] [Related]
29. Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor-sections.
Reznitsky FM; Jensen JD; Knoop A; Laenkholm AV
APMIS; 2022 Sep; 130(9):545-550. PubMed ID: 35639634
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
[TBL] [Abstract][Full Text] [Related]
31. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.
Gallardo A; Garcia-Valdecasas B; Murata P; Teran R; Lopez L; Barnadas A; Lerma E
Breast Cancer Res Treat; 2018 Jan; 167(1):31-37. PubMed ID: 28865009
[TBL] [Abstract][Full Text] [Related]
32. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
33. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.
Teleki I; Krenacs T; Szasz MA; Kulka J; Wichmann B; Leo C; Papassotiropoulos B; Riemenschnitter C; Moch H; Varga Z
BMC Cancer; 2013 Feb; 13():50. PubMed ID: 23374644
[TBL] [Abstract][Full Text] [Related]
34. Correlation of securin and Ki67 in invasive breast carcinoma.
Talaat IM; Hamoudi RA; Yakout NM; Oweiss NY; Omar AM
Histol Histopathol; 2019 Jun; 34(6):697-709. PubMed ID: 30506545
[TBL] [Abstract][Full Text] [Related]
35. Biological and clinical implications of nicastrin expression in invasive breast cancer.
Filipović A; Gronau JH; Green AR; Wang J; Vallath S; Shao D; Rasul S; Ellis IO; Yagüe E; Sturge J; Coombes RC
Breast Cancer Res Treat; 2011 Jan; 125(1):43-53. PubMed ID: 20224929
[TBL] [Abstract][Full Text] [Related]
36. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system.
Shim VC; Baker RJ; Jing W; Puentes R; Agersborg SS; Lee TK; GoreaI W; Achacoso N; Lee C; Villasenor M; Lin A; Kapali M; Habel LA
Breast Cancer Res Treat; 2024 Jan; 203(2):281-289. PubMed ID: 37847456
[TBL] [Abstract][Full Text] [Related]
38. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.
Serna G; Simonetti S; Fasani R; Pagliuca F; Guardia X; Gallego P; Jimenez J; Peg V; Saura C; Eppenberger-Castori S; Ramon Y Cajal S; Terracciano L; Nuciforo P
Breast; 2020 Oct; 53():102-110. PubMed ID: 32707454
[TBL] [Abstract][Full Text] [Related]
39. Comparative validation of the SP6 antibody to Ki67 in breast cancer.
Zabaglo L; Salter J; Anderson H; Quinn E; Hills M; Detre S; A'Hern R; Dowsett M
J Clin Pathol; 2010 Sep; 63(9):800-4. PubMed ID: 20671052
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
